SOHO 2021 Annual Meeting

Lisa Nodzon, PhD, ARNP, AOCNP, of the H...

Lisa Nodzon, PhD, ARNP, AOCNP, of the H...

Lisa Nodzon, PhD, ARNP, AOCNP, of the H...

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses updates on CAR T-cell therapy and what advanced practitioners need to be aware of when treating patients with rare lymphomas: how best to sequence these agents; the potential acute and long-term toxicities; available clinical trials; and appropriate referral to centers, especially for those who may not have many viable treatment options...

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses important data that advanced practitioners need to know about bispecific antibodies in the pipeline such as mosunetuzumab, glofitamab, and epcoritamab and how they may fit into the treatment paradigm; new antibody-drug conjugates; and how to sequence the agents, manage their toxicities, and deliver supportive care...

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such as treatment with pirobrutinib; other new agents such as parsaclisib, a PI3K delta inhibitor, and the bispecific agent epcoritamab; and CAR T-cell therapy...